Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

Heron Therapeutics: Acute Care Growth Offset by Oncology Weakness and Financial Uncertainty

Oct 20, 2026 | Team Kalkine
Heron Therapeutics: Acute Care Growth Offset by Oncology Weakness and Financial Uncertainty
Image source: shutterstock

  • HRTX:NASDAQ
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (US$)

Heron Therapeutics, Inc

Heron Therapeutics, Inc (NASDAQ: HRTX) is a commercial-stage biotechnology company developing and commercialising treatments for acute care and oncology supportive care. Its portfolio includes ZYNRELEF for postoperative pain, APONVIE for preventing postoperative nausea and vomiting, and CINVANTI and SUSTOL for preventing chemotherapy-induced nausea and vomiting.

Latest Business Development


Disclaimer-

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…